C WorldWide Group Holding A S Sells 36,000 Shares of Insulet Corporation (NASDAQ:PODD)

C WorldWide Group Holding A S decreased its position in Insulet Corporation (NASDAQ:PODD) by 24.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 111,908 shares of the medical instruments supplier’s stock after selling 36,000 shares during the period. Insulet comprises approximately 0.4% of C WorldWide Group Holding A S’s portfolio, making the stock its 27th biggest holding. C WorldWide Group Holding A S owned about 0.16% of Insulet worth $29,388,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Commonwealth Equity Services LLC lifted its stake in Insulet by 3.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 16,665 shares of the medical instruments supplier’s stock worth $4,351,000 after acquiring an additional 508 shares during the period. Natixis Advisors LLC lifted its stake in Insulet by 33.8% in the fourth quarter. Natixis Advisors LLC now owns 44,371 shares of the medical instruments supplier’s stock worth $11,584,000 after acquiring an additional 11,210 shares during the period. Envestnet Portfolio Solutions Inc. lifted its stake in Insulet by 2.3% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier’s stock worth $552,000 after acquiring an additional 48 shares during the period. Cibc World Markets Corp lifted its stake in Insulet by 46.1% in the fourth quarter. Cibc World Markets Corp now owns 13,851 shares of the medical instruments supplier’s stock worth $3,616,000 after acquiring an additional 4,368 shares during the period. Finally, Horizon Investments LLC lifted its stake in Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock worth $362,000 after acquiring an additional 42 shares during the period.

Insulet Trading Up 0.3%

Shares of NASDAQ:PODD traded up $0.94 on Friday, hitting $284.39. 48,699 shares of the company’s stock were exchanged, compared to its average volume of 780,837. Insulet Corporation has a 12 month low of $173.00 and a 12 month high of $329.33. The stock has a market capitalization of $20.02 billion, a price-to-earnings ratio of 51.19, a price-to-earnings-growth ratio of 2.57 and a beta of 1.35. The business’s 50 day simple moving average is $309.59 and its two-hundred day simple moving average is $280.69. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same period last year, the company earned $0.73 earnings per share. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. Analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the business’s stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president owned 23,180 shares in the company, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.39% of the stock is owned by company insiders.

Analysts Set New Price Targets

PODD has been the subject of a number of research analyst reports. Oppenheimer raised their price target on Insulet from $312.00 to $324.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. The Goldman Sachs Group initiated coverage on Insulet in a research report on Friday, May 30th. They issued a “buy” rating and a $380.00 target price for the company. Sanford C. Bernstein reissued an “outperform” rating on shares of Insulet in a research report on Friday, May 16th. Raymond James Financial reaffirmed an “outperform” rating and set a $360.00 price target (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Finally, Wall Street Zen lowered shares of Insulet from a “buy” rating to a “hold” rating in a research report on Saturday, June 14th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.